natgillin/translations-raw huggingface dataset:
In those patients treated in the pivotal study, the rate of severe infections declined throughout the follow-up period (Table 2).
Pri bolnikih, ki so se zdravili v ključni študiji, je delež hudih okužb med obdobjem spremljanja upadal (preglednica 2).
In those patients where the same line has to be used, this line (including Y-line) must be flushed thoroughly with 0.9 % sodium chloride or 5 % glucose solution prior to and following the Rapilysin injection.
Pri bolnikih, kjer je nujno uporabiti isti kanal, je treba ta kanal (vključno z Y-kanalom) temeljito izprati z 0,9 % fiziološko raztopino ali 5 % raztopino glukoze pred injiciranjem zdravila Rapilysin in po njem.
In those patients where the same line has to be used, this line (including Y-line) must be flushed thoroughly with a 0.9 % sodium chloride or 5 % glucose solution prior to and following the Rapilysin injection (see section 4.2 Posology and method of administration).
Pri bolnikih, kjer je nujno uporabiti isti kanal, je treba ta kanal (vključno z Y-kanalom) temeljito izprati z 0,9-% fiziološko raztopino ali 5-% raztopino glukoze pred injiciranjem zdravila Rapilysin in po njem (glejte 4.2 Odmerjanje in način uporabe).
In those patients where the same line has to be used, this line (including Y-line) must be flushed thoroughly with a 0.9 % sodium chloride or 5 % glucose solution prior to and following the Rapilysin injection.
Pri bolnikih, kjer je nujno uporabiti isti kanal, je treba ta kanal (vključno z Y-kanalom) temeljito izprati z 0,9-% fiziološko raztopino ali 5-% raztopino glukoze pred injiciranjem zdravila Rapilysin in po njem.
In those patients who are stable on alpha-blocker therapy, vardenafil should be initiated at the lowest recommended starting dose of 5 mg film-coated tablets.
Za bolnike, ki se zdravijo z zaviralci adrenergičnih receptorjev alfa in katerih zdravstveno stanje je stabilno, je zdravljenje z vardenafilom priporočljivo začeti z najmanjšim začetnim odmerkom – 5 mg filmsko obloženimi tabletami.
In those patients who are stable on alpha-blocker therapy, vardenafil should be initiated at the lowest recommended starting dose of 5 mg.
Pri bolnikih, ki jemljejo zaviralec receptorjev alfa in katerih zdravstveno stanje je stabilno, je treba začeti jemati najmanjši priporočeni odmerek vardenafila, to je 5 mg.
In those patients who initially received infliximab and then switched to abatacept, the reduction in the mean DAS28 score from baseline were 3.29 at day 729 and 2.48 at day 365.
Pri bolnikih, ki so v začetku prejemali infliksimab in so nato prešli na zdravljenje z abataceptom, je zmanjšanje povprečne vrednosti DAS28 od izhodišča na 729. dan znašalo 3,29, na 365. dan pa 2,48.
In those patients who underwent non-primary PCI <6 hours after the last dose of fondaparinux, the median dose of UFH was 5000 IU and the incidence of major bleeding was 4.1% (2/49).
Pri bolnikih, pri katerih je bila opravljena neprimarna PCI < 6 ur po zadnjem odmerku fondaparinuksa, je bil povprečni odmerek nefrakcioniranega heparina 5.000 i.e., pojavnost večjih krvavitev pa 4,1 % (2/49).
In those target animal safety studies, clinical signs of toxicity were reversible in some dogs following cessation of therapy.
Stranski učinki so izginili, ko je bilo zdravljenje prekinjeno.
In those who received the second vaccine 3 weeks to 5 years after vaccination with Pandemic influenza vaccine H5N1 MedImmune, antibodies increased 4-fold in 73% (8 out of 11) of the individuals compared with 10% of the individuals who had not been previously vaccinated with Pandemic influenza vaccine H5N1 MedImmune.
Pri tistih, ki so drugo cepivo prejeli po preteku treh tednov do petih let po cepljenju s cepivom proti pandemski gripi H5N1 MedImmune, so protitelesa štirikratno porasla pri 73 % (8 od 11 oseb) oseb, v primerjavi z 10 % oseb, ki niso bile cepljene s cepivom proti pandemski gripi H5N1 MedImmune.
In three comparative controlled trials, the immune response elicited by Rotarix liquid formulation was comparable to the one elicited by Rotarix lyophilised formulation.
V treh primerjalnih nadzorovanih preskušanjih je bil imunski odziv po aplikaciji tekoče oblike cepiva Rotarix primerljiv z imunskim odzivom po aplikaciji liofilizirane oblike cepiva Rotarix.
In three large clinical trials measuring patient-reported flushing symptoms, patients taking Tredaptive experienced less flushing than those taking nicotinic acid (prolonged-release formulations).
V treh velikih kliničnih preskušanjih, v katerih so ugotavljali simptome zardevanja po navedbi bolnikov, je bilo zardevanja manj med bolniki, ki so prejemali zdravilo Tredaptive, kot med bolniki, ki so prejemali nikotinsko kislino (pripravek s podaljšanim sproščanjem).
In three main studies involving 3,292 women who needed to have ovarian stimulation, Elonva treatment was compared with treatment with follitropin beta (an FSH medicine also used to stimulate the ovaries).
V treh glavnih študijah, v katerih je sodelovalo 3 292 žensk, ki so potrebovale spodbujanje jajčnikov, so zdravljenje z zdravilom Elonva primerjali z zdravljenjem s folitropinom beta (zdravilom s FSH, ki se tudi uporablja za spodbujanje jajčnikov).
In three main studies involving over 4,000 patients with COPD, Hirobriz Breezhaler at different doses has been compared with placebo (a dummy treatment), tiotropium or formoterol (other inhaled medicines used to treat COPD).
V treh glavnih študijah, ki so vključevale več kot 4 000 bolnikov s KOPB, so različne odmerke zdravila Hirobriz Breezhaler primerjali s placebom (zdravilom brez zdravilne učinkovine), tiotropiumom ali formoterolom (drugima inhalacijskima zdraviloma, ki se uporabljata za zdravljenje KOPB).
In three main studies involving over 4,000 patients with COPD, Onbrez Breezhaler at different doses has been compared with placebo (a dummy treatment), tiotropium or formoterol (other inhaled medicines used to treat COPD).
V treh glavnih študijah, ki so vključevale več kot 4 000 bolnikov s KOPB, so različne odmerke zdravila Onbrez Breezhaler primerjali s placebom (zdravilom brez zdravilne učinkovine), tiotropiumom ali formoterolom (drugima inhalacijskima zdraviloma, ki se uporabljata za zdravljenje KOPB).
In three main studies involving over 4,000 patients with COPD, Oslif Breezhaler at different doses has been compared with placebo (a dummy treatment), tiotropium or formoterol (other inhaled medicines used to treat COPD).
V treh glavnih študijah, ki so vključevale več kot 4 000 bolnikov s KOPB, so različne odmerke zdravila Oslif Breezhaler primerjali s placebom (zdravilom brez zdravilne učinkovine), tiotropiumom ali formoterolom (drugima inhalacijskima zdraviloma, ki se uporabljata za zdravljenje KOPB).
In three of four patients the change in the sweat chloride test was <5 mmol/L and this group did not demonstrate a clinically relevant improvement in FEV1 after 8 weeks of treatment.
Pri treh od štirih bolnikov se je test kloridov v znoju spremenil za <5 mmol/l in ta skupina ni pokazala klinično pomembnega izboljšanja FEV1 po 8 tednih zdravljenja.
In three of these studies, RoActemra was compared with placebo, as an add-on to failing treatment with conventional rheumatoid arthritis medicines in a total of over 3,000 patients.
V treh študijah so zdravilo RoActemra primerjali s placebom pri več kot 3 000 bolnikih kot dodatek k neuspešnemu zdravljenju z običajnimi zdravili proti revmatoidnemu artritisu.
In three phase III active-controlled clinical trials in patients with advanced malignancies involving bone, hypocalcaemia was reported in 9.6% of patients treated with XGEVA and 5.0% of patients treated with zoledronic acid.
V treh kliničnih preskušanjih III. faze, kontroliranih z zdravilno učinkovino, pri bolnikih z napredovanimi malignomi, ki so zajeli kosti, so poročali o hipokalciemiji pri 9,6 % bolnikov, ki so prejemali zdravilo XGEVA, in pri 5,0 % bolnikov, ki so prejemali zoledronsko kislino.
In three placebo-controlled trials (n = 938; mean age: 82.4 years; range: 56-99 years) of aripiprazole in elderly patients with psychosis associated with Alzheimer's disease, patients treated with aripiprazole were at increased risk of death compared to placebo.
V treh s placebom nadzorovanih preskušanjih (n = 938, povprečna starost: 82,4 leta, razpon: 56-99 let) aripiprazola pri starejših bolnikih s psihozo, povezano z Alzheimerjevo boleznijo, je bilo tveganje smrti večje pri bolnikih, ki so dobivali aripiprazol, kot pri tistih, ki so dobivali placebo.
In three placebo-controlled trials of oral aripiprazole in elderly patients with psychosis associated with Alzheimer's disease (n = 938; mean age: 82.4 years; range: 56-99 years), patients treated with aripiprazole were at an increased risk of death compared to placebo.
V treh s placebom nadzorovanih preskušanjih peroralnega aripiprazola pri starejših bolnikih s psihozo, povezano z Alzheimerjevo boleznijo (n = 938; povprečna starost: 82,4 let; razpon: 56–99 let), je bilo tveganje smrti večje pri bolnikih, ki so dobivali aripiprazol, kot pri tistih, ki so dobivali placebo.
In total 1623 patients were enrolled into the study, with 535 patients randomized to Rd, 541 patients randomized to Rd18 and 547 patients randomized to MPT.
Vsega skupaj je bilo v študijo vključenih 1.623 bolnikov, od teh je bilo 535 bolnikov randomiziranih na Rd, 541 bolnikov na Rd18 in 547 bolnikov na MPT.
In total 21,988 administrations of CEPROTIN have been given.
Zdravilo CEPROTIN so bolnikom dali skupaj 21.988-krat.
In total 459 patients were enrolled into the study, with 152 patients randomized to MPR+R, 153 patients randomized to MPR+p and 154 patients randomized to MPp+p.
Vsega skupaj je bilo v študijo vključenih 459 bolnikov, od teh je bilo 152 bolnikov randomiziranih na MPR+R, 153 na MPR+p in 154 na MPp+p.
In total about 67 % of patients exposed to at least one dose of rivaroxaban were reported with treatment emergent adverse events.
Skupaj so pri približno 67 % bolnikov, ki so prejeli vsaj en odmerek rivaroksabana, poročali o neželenih učinkih, povezanih z zdravljenjem.
In total about 67% of patients exposed to at least one dose of rivaroxaban were reported with treatment emergent adverse events.
Skupaj so pri približno 67 % bolnikov, ki so prejeli vsaj en odmerek rivaroksabana, poročali o neželenih učinkih, povezanih z zdravljenjem.
In total eight studies, conducted in various countries across Europe, in Chile and in the Philippines, have evaluated the immunogenicity of Synflorix after a three-dose primary series (N=3,089) according to different vaccination schedules (6-10-14 weeks, 2-3-4, 3-4-5 or 2-4-6 months of age).
Skupaj osem študij, opravljenih v različnih državah po Evropi ter v Čilu in na Filipinih, je ocenilo imunogenost Synflorixa po primarnem zaporedju cepljenja s tremi odmerki (n = 3.089) po različnih razporedih cepljenja (pri 6-10-14 tednih ali pa 2-3-4, 3-4-5 ali 2-4-6 mesecih starosti).
In total there were 60 primary events on linagliptin and 62 on comparators.
Med uporabo linagliptina je bilo skupno 60 primarnih dogodkov, med uporabo primerjalnih zdravil pa 62.
In total there were 60 primary events on linagliptin and 62 on comparators.
Skupno je bilo pri linagliptinu 60 primarnih dogodkov, pri komparatorjih pa 62.
In total, 199 patients with GIST were randomized 2:1 to receive either 160 mg regorafenib plus Best Supportive Care (BSC; N=133) orally once daily or matching placebo plus BSC (N=66) for 3 weeks on therapy followed by 1 week off therapy.
Skupaj je bilo 199 bolnikov z GIST randomiziranih 2:1 v skupino, ki je prejemala 160 mg regorafeniba peroralno enkrat na dan in najboljšo podporno oskrbo (BSC; N = 133) ali ustrezen placebo (N = 66) in najboljšo podporno oskrbo, 3 tedne zdravljenja, ki jim je sledil 1 teden brez zdravljenja.
In total, 2,076 patients were evaluated (692 patients on 150 mg, 690 patients on 300 mg and 694 patients on placebo).
Skupno so ovrednotili podatke 2.076 bolnikov (692 bolnikov je prejemalo odmerek 150 mg, 690 jih je prejemalo odmerek 300 mg, 694 pa placebo).
In total, 22 % of patient with atrial fibrillation treated for the prevention of stroke and SEE (long-term treatment for up to 3 years) , 14 % of patients treated for DVT/PE and 15 % of patients treated for DVT/PE preventionexperienced adverse reactions.
Skupno so se neželene reakcije pojavile pri 22 % bolnikov z atrijsko fibrilacijo, ki so zdravilo jemali za preprečitev možganske kapi in sistemskih emboličnih dogodkov (dolgotrajno zdravljenje do 3 leta), pri 14 % bolnikov, ki so se zdravili zaradi GVT/PE in pri 15 % bolnikov, ki so zdravljenje prejemali za preprečitev GVT/PE.
In total, 760 patients were randomised 2:1 to receive 160 mg regorafenib (4 tablets Stivarga each containing 40 mg regorafenib) orally once daily (N=505) plus Best Supportive Care (BSC) or matching placebo (N=255) plus BSC for 3 weeks on therapy followed by 1 week off therapy.
Skupaj je bilo 760 bolnikov randomiziranih 2:1 v skupino, ki je prejemala 160 mg regorafeniba (4 tablete zdravila Stivarga; ena tableta vsebuje 40 mg regorafeniba) peroralno enkrat na dan (N = 505) in najboljšo podporno oskrbo (BSC) ali ustrezen placebo (N = 255) in najboljšo podporno oskrbo 3 tedne zdravljenja, ki jim je sledil 1 teden brez zdravljenja.
In total, 800 patients were randomised 2:1 to receive Lonsurf (N = 534) plus best supportive care (BSC) or matching placebo (N = 266) plus BSC.
Skupaj je bilo 800 bolnikov randomiziranih 2:1 v skupino, ki je prejemala zdravilo Lonsurf (N = 534) in najboljšo podporno oskrbo (BSC – Best Supportive Care) ali ustrezen placebo (N = 266) in BSC.
In total, 99 out of 8956 patients reported an event in the vildagliptin group vs 91 out of 6061 patients in the comparator group.
Skupno so o katerem od teh dogodkov poročali pri 99 od 8.956 bolnikov, ki so prejemali vildagliptin, v primerjavi z 91 od 6.061 bolnikov iz skupin s primerjalnimi zdravili.
In total, data to support the use of Wilzin came from 255 patients with Wilson’s disease.
Podatki v podporo uporabi zdravila Wilzin prihajajo skupaj od 255 bolnikov z Wilsonovo boleznijo.
In toxicity studies with multiple intramuscular doses of fulvestrant in rats and dogs, the anti- estrogenic activity of fulvestrant was responsible for most of the effects seen, particularly in the female reproductive system, but also in other organs sensitive to hormones in both sexes.
V študijah toksičnosti na podganah in psih s ponavljajočimi intramuskularnimi odmerki fulvestranta je bilo njegovo antiestrogeno delovanje odgovorno za večino opaženih učinkov, posebej na reprodukcijskem sistemu samic, pa tudi na drugih organih, občutljivih na hormone pri obeh spolih.
In TRA 2°P - TIMI 50, 367 post-MI or PAD patients with no history of stroke or TIA underwent CABG surgery.
V študiji TRA 2°P – TIMI 50 je bila CABG opravljena pri 367 bolnikih po MI ali PAD, ki v anamnezi niso imeli možganske kapi ali TIA.
In TRA 2°P - TIMI 50, among patients who entered the trial, those with a history of ischaemic stroke had a higher 3 year K-M event rate for ICH on Zontivity plus standard care (2.7%) than on standard care alone (0.9%).
V študiji TRA 2°P – TIMI 50 so imeli vključeni bolniki z anamnezo ishemične možganske kapi večji 3-letni po K-M ocenjeni delež dogodkov ICH z zdravilom Zontivity in standardno oskrbo (2,7 %) kot s standardno oskrbo samo (0,9 %).
In TRA 2°P - TIMI 50, in vorapaxar- treated patients, including those with history of stroke, a higher rate of ICH was observed in patients weighing <60 kg compared to patients weighing ≥60 kg.
V preskušanju TRA 2ºP-TIMI 50 pri bolnikih, ki so prejemali vorapaksar, vključno s tistimi z možgansko kapjo v anamnezi, so pri tistih, s telesno maso < 60 kg, opazili večji delež ICH kot pri tistih, s telesno maso ≥ 60 kg.
In treatment naïve patients, the clinical study data on use of raltegravir are limited to use in combination with two nucleotide reverse transcriptase inhibitors (NRTIs) (emtricitabine and tenofovir disoproxil fumarate).
Za zdravljenje predhodno nezdravljenih bolnikov je iz kliničnih študij na voljo malo podatkov glede uporabe raltegravirja v kombinaciji z dvema nukleozidnima zaviralcema reverzne transkriptaze (NRTI) (emtricitabin in tenofovirdizoproksil fumarat).
In treatment- experienced patients, the number of patients switching from lamivudine to Emtriva with viral loads below 400 copies/ml was similar to the number who continued taking lamivudine after 48 weeks (73% and 82%, respectively).
Pri zdravljenju bolnikov, ki so se zdravili že prej, je bilo število tistih, ki so prešli iz lamivudina na zdravilo Emtriva in pri katerih je bila virusna obremenitev manjša od 400 kopij/ml, podobno številu bolnikov, ki so po 48 tednih zdravljenja še naprej jemali lamivudin (73 % oziroma 82 %).
In treatment-experienced patients
Pri predhodno zdravljenih bolnikih
In treatment-experienced patients, Isentress was more effective than placebo: 77% of the patients who took Isentress had viral loads below 400 copies/ml after 16 weeks, compared with 42% of those who took placebo.
Pri zdravljenju predhodno že zdravljenih bolnikov je bilo zdravilo Isentress učinkovitejše od placeba: po 16 tednih je bilo virusno breme pod 400 kopij/ml pri 77 % bolnikov, ki so jemali zdravilo Isentress, v primerjavi z 42 % bolnikov, ki so prejemali placebo.
In treatment-experienced patients, the two randomised clinical studies used the recommended dose of 400 mg twice daily in combination with optimised background therapy (OBT) in 462 patients, in comparison to 237 patients taking placebo in combination with OBT.
V dveh randomiziranih kliničnih študijah pri predhodno že zdravljenih bolnikih so pri 462 bolnikih uporabili priporočeni odmerek 400 mg dvakrat na dan v kombinaciji z optimiziranim osnovnim zdravljenjem (OBT - optimized background therapy), v primerjavi z 237 bolniki, ki so v kombinaciji z OBT prejemali placebo.
In treatment-naïve adult subjects
Pri odraslih bolnikih, ki še niso prejemali protiretrovirusnih zdravil
In treatment-naïve MRCC patients receiving IFN-, six (2%) venous thromboembolic events occurred; one patient (<1%) experienced a Grade 3 DVT and five patients (1%) had pulmonary embolisms, all with Grade 4.
Med bolniki s še nezdravljenim MRCC, ki so prejemali IFN-, se je pojavilo 6 (2 %) venskih trombemboličnih dogodkov; pri enem bolniku (< 1 %) je šlo za globoko vensko trombozo 3. stopnje, pet bolnikov (1 %) pa je imelo pljučno embolijo 4. stopnje.
In treatment-naïve patients, a mean change from baseline of 0.04 ± 0.11 mg/dL (3.5 ± 9.7 μmol/L) was observed after 96 weeks of treatment.
Pri predhodno nezdravljenih bolnikih so po 96. tednih zdravljenja opazili povprečno spremembo od začetne vrednosti 0,04 ± 0,11 mg/dl (3,5 ± 9,7 μmol/l).
In treatment-naïve patients, the most frequently reported adverse reactions considered possibly or probably related to rilpivirine hydrochloride and emtricitabine/tenofovir disoproxil fumarate were nausea (9%), dizziness (8%), abnormal dreams (8%), headache (6%), diarrhoea (5%) and insomnia (5%) (pooled data from the Phase III clinical studies C209 and C215, see section 5.1).
Pri predhodno nezdravljenih bolnikih so bili najpogostejši neželeni učinki, ki so bili verjetno oziroma morda povezani z rilpivirinijevim kloridom in emtricitabinom/dizoproksiltenofovirijevim fumaratom, navzea (9 %), omotičnost (8 %), nenavadne sanje (8 %), glavobol (6 %), driska (5 %) in nespečnost (5 %) (podatki so združeni iz kliničnih študij faze III C209 in C215, glejte poglavje 5.1).
In treatment-naïve patients, the multi-centre, randomised, double-blind, active-controlled clinical study used the recommended dose of 400 mg twice daily in combination with a fixed dose of emtricitabine 200 mg (+) tenofovir 245 mg in 281 patients, in comparison to 282 patients taking efavirenz (EFV) 600 mg (at bedtime) in combination with emtricitabine (+) tenofovir.
V multicentrični, randomizirani, dvojno slepi, z zdravilno učinkovino nadzorovani klinični študiji pri predhodno nezdravljenih bolnikih so pri 281 bolnikih uporabili priporočeni odmerek 400 mg dvakrat na dan v kombinaciji s fiksnim odmerkom 200 mg emtricitabina (+) 245 mg tenofovirja, v primerjavi z 282 bolniki, ki so prejemali efavirenz v odmerku 600 mg (pred spanjem) v kombinaciji z emtricitabinom (+) tenofovirjem.
In trial SABRINA, severe administration-related reactions (grade≥3) were reported in two patients (2%) following administration of MabThera subcutaneous formulation .
V preskušanju SABRINA so pri dveh bolnikih (2 %) po uporabi podkožne oblike zdravila MabThera zabeležili hude reakcije (≥ 3. stopnje), povezane z dajanjem zdravila.
In trials where the application sites were rotated as reflected in the instructions provided in the SmPC and package leaflet, 34.2% of 748 patients using Leganto, experienced application site reactions.
Pri preskušanjih, v katerih so mesto aplikacije spreminjali po navodilih iz povzetka glavnih značilnosti zdravila in navodila za uporabo, so se reakcije na mestu aplikacije pojavile pri 34,2 % od
In trials where the application sites were rotated as reflected in the instructions provided in the SmPC and package leaflet, 34.2% of 748 patients using Neupro, experienced application site reactions.
Pri preskušanjih, v katerih so mesto aplikacije spreminjali po navodilih iz povzetka glavnih značilnosti zdravila in navodila za uporabo, so se reakcije na mestu aplikacije pojavile pri 34,2 % od
In trials with 5 times per week dosing 58% of patients experienced at least one adverse event.
V preskušanjih z odmerjanjem petkrat tedensko je 58% bolnikov razvilo najmanj en neželen dogodek.
In trials, children usually needed higher doses of NeoRecormon (the younger the child, the higher the dose).
V preskušanjih so otroci povprečno potrebovali večji odmerek zdravila NeoRecormon (čim mlajši je otrok, večji odmerek potrebuje).
In triple therapy, one study looked at the effect of adding rosiglitazone to a sulphonylurea (glibenclamide) and metformin in 1,202 patients whose blood glucose was not being controlled sufficiently.
V eni študiji zdravljenja s tremi zdravili hkrati so proučevali učinek dodajanja rosiglitazona sulfonilsečnini (glibenklamidu) in metforminu pri 1202 bolnikih, pri katerih glukoza v krvi ni bila zadostno uravnana.
In triple therapy, when starting treatment in patients who are already taking metformin and a sulphonylurea, Avandamet is given so that the patient receives 4 mg of rosiglitazone a day, and the same dose of metformin as before.
Ko začnemo zdravljenje s tremi zdravili hkrati pri bolnikih, ki že jemljejo metformin in sulfonilsečnino, se Avandamet daje tako, da bolnik prejme 4 mg rosiglitazona na dan in enak odmerek metformina, kot ga je dobival dotlej.
In TRITON, for every 1000 patients treated with Efient, there were 22 fewer patients with myocardial infarction, and 5 more with non–CABG-related TIMI major haemorrhages, compared with patients treated with clopidogrel.
V študiji TRITON je bilo na vsakih 1000 bolnikov, zdravljenih z zdravilom Efient, 22 manj bolnikov z miokardnim infarktom in 5 več z večjo krvavitvijo po TIMI, nepovezano s CABG, v primerjavi z bolniki, zdravljenimi s klopidogrelom.
In TRITON, the frequency of patients experiencing a non-CABG related bleeding event is shown in Table 1.
V študiji TRITON je pogostnost bolnikov, ki so imeli krvavitev, nepovezano s CABG, prikazana v Preglednici 1.
In TRIUMPH, study patients treated with Soliris had significantly reduced (p< 0.001) haemolysis resulting in improvements in anaemia as indicated by increased haemoglobin stabilization and reduced need for RBC transfusions compared to placebo treated patients (see Table 3).
V študiji TRIUMPH so imeli sodelujoči bolniki, zdravljeni z zdravilom Soliris, pomembno zmanjšano (p< 0,001) hemolizo, kar je privedlo do izboljšanja slabokrvnosti, kakor to kaže večja stabilizacija hemoglobina in zmanjšanje potrebe po transfuziji eritrocitov v primerjavi z bolniki, zdravljenimi s placebom (glejte preglednico 3).
In TRYPHAENA, the incidence of febrile neutropenia was higher in patients who received six cycles of Perjeta compared with patients who received three cycles of Perjeta, independent of the chemotherapy given.
TRYPHAENA je bila incidenca febrilne nevtropenije večja pri bolnikih, ki so prejeli 6 ciklov zdravila Perjeta, kot pri bolnikih, ki so prejeli le 3 cikle zdravila Perjeta, neodvisno od vrste dane kemoterapije.